Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07593209 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2

Study acronym: EphA2
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.
Trial Details
NCT Number NCT07593209
Lead Sponsor First Hospital of China Medical University
Conditions
(from sponsor)		 Malignant Tumor
Related terms Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov